INTRODUCTION
Multiple identi ed mechanisms by which tumors can evade control by the immune system illustrate the challenges in generating e ective and speci c antitumor immunity for therapeutic bene t. 1 Gene therapy with adenoviruses is a promising modality for the treatment of advanced cancer refractory to the other therapies. Importantly, the safety and the e cacy of this approach have been recently validated in several studies. [2] [3] [4] [5] [6] [7] [8] Classically, the immune system is thought to limit the e cacy of oncolytic adenoviruses, leading to their clearance. However, recent preclinical and clinical data suggest that in some cases virotherapy may in fact act as cancer vaccine stimulating tumorspeci c immune response. 5, 8, 9 e rationale behind these discoveries is that adenovirus can activate antigen-presenting cells, such as dendritic cells (DCs), via stimulation of pattern recognition receptors. Once activated, DCs can present tumor antigen epitopes to CD8+ and CD4+ T cells. Unfortunately, the frequency of activated CD8+ T cells is o en too low to mount an e ective response against the tumor, 10 especially when immune suppressive mechanisms are present as in advanced human tumors 11 hence it is important to investigate new strategies to augment DC stimulation and migration.
All the biologic responses crucial for DC functioning are in uenced by signaling through Toll-like receptors (TLRs). 12 TLRs are a group of receptors expressed primarily by cells of the innate immune system, and are activated by pathogen-associated molecular patterns. TLR9, 1 of the 11 TLRs identi ed in humans, is localized in late endosomes or lysosomes where it detects unmethylated CpG motifs in double-stranded DNA (CpG-DNA) from bacterial, viral, and human sources. [13] [14] [15] Upon activation, TLR9 induces DCs to secrete high levels of type I interferons (IFNs) and interleukin-12 (IL-12), leading to rapid activation of natural killer (NK) cell cytotoxicity and IFN- production 12 for a potent antitumor response. 16, 17 Agonists of TLR9 have demonstrated potential for the treatment of cancer. ey directly induce activation and maturation of DCs, enhance di erentiation of B cells into antibody-secreting plasma cells, activate T cells, 16, 17 and reduce inhibition by myeloidderived suppressor cells (MDSCs). 18, 19 MDSCs are a population of immature myeloid cells present in high numbers in a wide range of cancers. 11, 20 MDSCs accumulate due to a tumor-induced maturity block preventing di erentiation of myeloid precursors into antigen-presenting cells. 21 ey inhibit e ector T-cell proliferation in vitro and are thought to contribute to tumor-related immune suppression in vivo by inducing T-cell and NK-cell dysfunction. 22, 23 Murine MDSC are de ned by the coexpression of the granulocyte di erentiation antigen Gr1 (constituted by the two epitopes Ly6G and Ly6C) and the 1M integrin CD11b. 11 MDSC represent a heterogeneous cell population, further subdivided by the di erential expression of the Ly6G and Ly6C epitopes and the di erential expression of Ly6G has been used to distinguish between MDSC subpopulations. 24, 25 One possible way to increase DC activation is stimulation of TLR9; however, nearly all DNA viruses, including Ad5, have evolved to avoid TLR9 recognition by reducing their genomic content of CpG dinucleotides by 50-94% from what would be expected. 26 For this reason, we generated a CpG-rich oncolytic adenovirus to combine the e ect of oncolysis (which releases tumor-associated antigens) with targeted delivery of a CpG stimulating double-stranded DNA molecule to the endosome where TLR9 is located.
RESULTS
Combination of stimulatory CpG oligonucleotides (CpG) and oncolytic adenovirus results in an enhanced antitumor efficacy in a xenograft model of lung cancer Despite evolutionary reduction of the number of immunostimulatory sequences in the genome of adenoviruses, 26 we and others have demonstrated that adenoviruses are able to elicit antitumor immune responses, 5, 9 and mechanistic studies have revealed molecular interactions with di erent arms of the innate immune system. 27, 28 We hypothesized that the combination of oncolytic adenovirus with speci c oligonucleotides to stimulate TLR9 (e.g., ODN2395) would result in a more robust antitumor immune response and ultimately in improved e cacy. To this end, nude mice were implanted with subcutaneous A549 lung cancer xenogra s and treated with media only, CpG oligos only, oncolytic adenovirus Ad5D24 (which bears a 24 bp deletion in E1A gene to allow selective replication in p16/Rb pathway de cient cancer cells) 29 and a combination of Ad5D24 and CpG (Figure 1a) . Interestingly, we observed that Ad5D24 + CpG signi cantly reduced tumor growth not only compared with mock (P = 0.005) but also when compared with Ad5D24 alone (P = 0.016) and CpG alone (P = 0.027) suggesting that TLR9 stimulation has a synergistic e ect with oncolytic virotherapy.
e activation of NK cells is one of the most prominent mechanisms that have been proposed to explain the activity of TLR9 agonists. 16 Activated DCs secrete IL12, which activates NK cells to secrete IFN-. To study this, mouse splenocytes were harvested and cultured for 72 hours, media was collected and IL-12 and IFN- concentration were analyzed. We found that the levels of IL-12 ( Figure 1b) and IFN- (Figure 1c) were signi cantly higher in the group featuring the combination of Ad5D24 and CpG. is suggested that the e cacy observed in this group might have been mediated by the innate arm of the immune system, in particular by NK cells.
A genetically modified CpG-rich oncolytic adenovirus (Ad5D24-CpG) mediates increased NFB activation but retains oncolytic potency As the combination of CpG and oncolytic adenovirus (Ad5D24) resulted in an increased antitumor e ect (Figure 1 ) and given that adenoviruses genome has evolved to reduce TLR9 stimulatory sequences, 26 we hypothesized that inserting CpG islands back into the genome would result in a synergistic antitumor e cacy with no additional need for administration of oligonucleotides. To this end, Ad5D24-CpG was generated by direct cloning of synthetic CpG island (18 islands) into the virus genome with no alterations of any of the adenovirus open reading frames (Figure 2a) .
Because TLR9 stimulation culminates in nuclear factor B (NFB) activation, we assessed the functionality of the new virus in 293 cells expressing TLR9 but no other TLRs and featuring luciferase driven by an NFB-inducible promoter. At di erent doses and time points, we constantly observed a signi cant increase in NFB activation when the cells were infected with the CpG-rich adenovirus (Figure 2b) .
We next sought to investigate whether or not the capability of killing cancer cells in vitro was maintained. To this end, 3-(4,5,dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay was performed on di erent human cancer cell lines. We observed that Ad5D24-CpG was slightly less e ective than Ad5D24 only in SKOV3 at 1 and 10 virus particle (VP)/cell and in PC3MM2 10 VP/cell (Figure 2c) .
ese small di erences could not be due to the VP/PFU (plaqueforming unit) ratio that was in slight favor of Ad5D24-CpG (10 versus 50 VP/PFU), but we can speculate that the more immunogenic nature of the CpG virus could lead the cell in a more stringent antiviral state that is able to slower its replication. However, Ad5D24-CpG was able to kill most cells and therefore we concluded that the virus retained its lytic capacity. Ad5D24-CpG retains the safety profile of the maternal Ad5D24 but it shows enhanced immunogenicity Used at high doses, adenoviruses can constitute a real concern in terms of toxicity. 30 Although the safety pro le of cancer treatment with oncolytic adenoviruses has been excellent, [31] [32] [33] [34] [35] [36] it is conceivable that increasing the CpG content in the adenovirus genome could result in increased toxicity due to higher stimulation of TLR9 and consequent cytokine storm. To address this, we studied immediate and late cytokine levels, liver tropism and toxicity of the viruses, and ultimately the kinetics of viral clearance.
To this end, immunocompetent C57BL/6 mice were intravenously injected with a high dose of virus. Mice were bled at early time point (6 hours) and at later time points (72 hours) and proinammatory cytokines were analyzed. e rst time point (6 hours) is indicative of the immediate toxicity, mainly due to the interaction of the viral capsid with di erent cell types of the immune system. e second time point (72 hours) is indicative of intermediate toxicity due to the replication of the genome and the production of viral proteins.
30
, [37] [38] [39] Although both viruses (Ad5D24 and Ad5D24-CpG) induced a signi cant increase of cytokines at 6 and 72 hours compared with phosphate-bu ered saline (PBS)-treated mice, we did not observe any signi cant di erence between them (Figure 3a) . At 6 days postadministration, there is still evidence of hepatocytes' apoptosis and T-cell in ltration, but to a far lower degree than at 72 hours postinfection. e T-cell in ltrate is seen predominantly in portal areas and lesser in sinusoids, without evidence of further cell recruitment. e degree of cell death and T-cell in ltration is lower in animals infected with Ad5D24-CpG (Supplementary Figure  S2a-d) . At 9 days postinfection, the in ammatory (T cell) in ltration has further subsided signi cantly and there is no evidence of cell death. Again, the degree of leukocyte in ltration is lower in animals infected with Ad5D24-CpG (Supplementary Figure S2e,f) .
Weight loss and survival were monitored and no signi cant di erences were observed between the three di erent groups (Supplementary Figure S3a,b) .
To test the immunogenicity of the CpG-rich backbone, splenocytes of immunocompetent mice intramuscularly vaccinated with the viruses (Ad5D24, Ad5D24-CpG) or PBS as control, were harvested pulsed with Ad5-speci c peptides and -ELISPOT was performed. Interestingly, we found a signi cant increase of splenocytes-secreting IFN- in the group of mice immunized with Ad5D24-CpG, which was not observed when splenocytes were pulsed with an irrelevant peptide (Figure 3b) .
To assess whether the new viral backbone would have an impact on replication of the virus and consequently on its liver toxicity, the kinetics of the viral genomes was studied by quantitative PCR ( Figure 4 ). As expected, we did not observe signi cant 8 VP/mouse of Ad5D24 (white), Ad5D24-CpG (gray), and PBS (black). Three weeks later, splenocytes were harvested from the mice pulsed with adenovirus 5-derived peptides and IFN-ELISPOT was performed. P values; *P < 0.05, **P < 0.01. IFN-, interferon-; IL, interleukin; PBS, phosphate-buffered saline; PSA, prostate-specific antigen; RANTES, regulated upon activation, normal T-cell expressed, and secreted; SFU, standard fluorescence unit; TNF-, tumor necrosis factor-; VP, virus particle. di erences in the liver (P = 0.16) or in the clot (P = 0.13) at 6 hours indicating that the transduction of the virus has remained unaltered. Also, identical amounts of virus DNA detected in the liver con rm that dosing and the titers of the viruses were equivalent. At 72 hours, we observed a signi cant increase of Ad5D24 genomes in both the clot (P = 0.01) and liver (P = 0.007) suggesting a more active replication of this virus. ese ndings well correlate with the in vitro experiment results described in Figure 2c . No di erences were observed at the later time points (6 and 9 days a er virus administration).
Ad5D24-CpG displays a TLR9-mediated NK-dependent enhanced antitumor effect in a xenograft model of lung cancer
In a mouse model of human lung cancer, Ad5D24 was more e ective than mock but adding recombinant CpG oligonucleotide did not signi cantly enhance e cacy (Figure 5a) . In contrast, Ad5D24-CpG was superior to the combination group, highlighting the utility of targeted delivery of the CpG-rich adenoviral genome to the endosome where TLR9 is located.
On day 12, mice were euthanized and spleens were collected for further analysis. e cytokine pro le (Figure 5b) suggested that NK activation might be involved in the enhanced antitumor response, especially in absence of T cells in athymic nude mice. To study this further, we analyzed the proportion of NK cells in spleens of treated mice (Supplementary Figure S4) . Interestingly, we found that in mice treated with Ad5D24-CpG, the percentage of NK cells was higher than in controls.
Stimulated splenocytes were then cocultured with tumor cells at di erent ratios and a er 72 hours the viability of target cells was measured (Supplementary Figure S5) . Intriguingly, splenocytes harvested from mice treated with Ad5D24-CpG showed a signi cantly increased cell-killing activity which is in line with the hypothesis that the treatment might have upregulated NK cells (Supplementary Figure S4) . When splenocytes from this experiment were cocultured with di erent target cell line (SKOV3, BT474, and 293), we also observed some degree of cell killing (Supplementary Figure S6) . ese results are in line with an NK cells-mediated cell-killing e ect.
To con rm the role of the NK cells in this tumor model, the experiment was repeated with prior depletion of NK cells. Interestingly, we observed that in the absence of NK cells, Ad5D24-CpG lost its advantage on the regular Ad5D24 virus (Figure 5c) .
To assess the role of TLR9-binding on the activity of the CpGrich oncolytic adenovirus, an experiment was performed with simultaneous TLR9-blockage. 28 is also resulted in Ad5D24-CpG losing its advantage on Ad5D24 (Figure 5d ). Taken together, these experiments suggest that the CpG-enriched adenovirus genome is able to stimulate TLR9 resulting in an NK-mediated improvement in antitumor response.
Ad5D24-CpG displays increased efficacy and enhanced antitumor immune response in a syngeneic model of melanoma Xenogra models in nude mice are limited by the lack of an intact immune system. Although we found NK cells to be important players in this model, we could not exclude that other cells might also be relevant in the presence of a full immune system. It has been previously demonstrated that adenovirus-based therapy can stimulate a tumor-speci c immune response. 5, 9 However, the impact of stimulation of TLR9 with a CpG-rich oncolytic adenovirus on the tumor-speci c immune response has not been previously studied. To answer these questions, we performed an additional set of experiments using a syngeneic murine model of melanoma stably transfected with chicken ovalbumin (B16-OVA), that allows accurate assessment of tumor speci c T-cell responses. e syngeneic model has the advantage of the intact immune system but it has the limitation that serotype 5-based oncolytic adenoviruses do not kill murine cells due to species-speci c incompatibility. 40 Hence the e ect observed in the following experiments can only rely on the activation of the immune system.
We observed that Ad5D24-CpG signi cantly enhanced tumor control compared with Ad5D24 or the combination of Ad5D24 with recombinant CpG oligonucleotides (Figure 6a) . Because stimulation of TLR9 can lead to T-cell activation, we analyzed the anti-OVA-speci c T cell as a surrogate of antitumor immunity in the spleen and directly in the tumors (Figure 6b,c) . Interestingly, we found that the number of CD8+ and the number of the anti-OVA speci c T cells was signi cantly higher in mice treated with Ad5D24-CpG in the spleen and in the tumor (Figure 6b,c) . Percentage of myeloid-derived suppressor cells, defined as positive for granzyme (Gr+) and CD11b. Percentage of Ly6G epitope positive cells was analyzed as a functional marker of the immunosuppressivity of the CD11b+Gr+ population. P values where not indicated; *P < 0.05, **P < 0.01, ***P < 0.001. VP, virus particle.
Because it has been recently demonstrated that CpG oligonucleotide therapy blocks immune suppression by MDSCs in tumorbearing mice, 19, 41 we also analyzed the percentage of MDSCs. Interestingly, in spleen although we did not observe quantitative di erences between the di erent groups (Figure 6d) , when a marker of their suppressivity (Ly-6G) was taken into account, a signi cant reduction was seen with Ad5D24-CpG (Figure 6d) . When the analysis was repeated in the tumors, we observed a signi cant reduction of total number and activation of MDSCs (Figure 6e) .
DISCUSSION
is report outlines a novel immunotherapeutic approach to genetically modify oncolytic adenoviruses by enriching their genome with CpG islands. e combination of selective and selfpropagating tumor cell killing with immunostimulation is important, as it may facilitate changes in the tumor microenvironment. Speci cally, this approach could result in switching from limited antigen presentation and activation to an e ective priming of tumor-speci c CD8+ T cells with potent e ector function.
We found that a genetically modi ed CpG-rich oncolytic adenovirus (Ad5D24-CpG) shows enhanced antitumor activity in conjunction with a capacity for activation of the innate and adaptive immune systems toward the tumor.
First, we showed that the combination of CpG containing oligonucleotide CpG and oncolytic adenovirus therapy is synergistic (Figure 1) . ese results are well in line with what was previously demonstrated by Van Oosten and colleagues that a TRAILexpressing adenovirus in combination with CpG oligonucleotide treatment resulted in enhanced e cacy dependent on CD8+ T cells. 10 In our model, the lack of T cells is compensated by the activation of NK cells as demonstrated in similar animal models where only CpG oligonucleotide therapy was given. 16 e limitations of combining two separate agents are several, from the cost of the oligonucleotides to their inactivation by nuclease. Also, two agents would disseminate to di erent cell compartments resulting in suboptimal concentrations at the target. e amount of oligonucleotides reaching the endosome a er intravenous delivery is not known but it is likely to constitute a small fraction of the initial administered dose. In contrast, oncolytic replication ampli es locally at tumors, and adenovirus is an optimal vehicle for delivery of DNA to endosomes, because infection proceeds through them.
In a xenogra model of lung cancer, we showed that the CpGrich adenovirus displayed increased antitumor activity compared not only with an oncolytic adenovirus alone but also with the combination of the oncolytic adenovirus and CpG oligonucleotides. One of the reasons for this phenomenon could be that while the pharmacokinetics of the oligonucleotide results in metabolic elimination from the host, the CpG-rich virus can constantly and sustainably replicate in tumor cells, transduce nearby antigenpresenting cells and stimulate the TLR9. Along this line, Raykov and colleagues inserted CpG motifs in a parvovirus to enhance its antitumor activity. 42 However, because the animal model used was a rat, only limited immunological analyses were performed and thus the mechanism for additive e ects was not fully analyzed.
Our experiments in nude mice highlight the involvement of the innate immune system (in absence of T cells) and in particular the cytokine pro le of the splenocytes harvested from the treated mice indicated an activation of NK cells. 16, 17 is was con rmed in a coculture experiment where splenocytes from the treated mice were cocultured with di erent cell lines. We observed that splenocytes from mice treated with the CpG-rich adenovirus displayed a more pronounced ability to kill cancer cells within 24 hours, which is typical of fast-acting NK cells. Also, increased numbers of NK cells were seen in mice treated with Ad5D24-CpG. Interestingly, when we performed the same experiment in NK cell-depleted mice, the CpG-virus lost its advantage suggesting a direct involvement of NK cells in tumor clearance. ese results are well in line with what has been previously observed with CpG therapy alone and what has been proposed as the mechanism of action of CpG in nude mice. 16, 17 e proposed mechanism of action of TLR9 agonists is the stimulation of the innate and adaptive antitumor immune responses via secretion of IFN- from immature plasmacytoid DCs, which activates NK cells to lyse tumor cells and release tumor antigens. DCs activated directly or indirectly by the TLR9 agonist therapy can capture and process tumor-associated antigens, increase surface expression of major histocompatibility complex and costimulatory receptors, and migrate to the lymph nodes where antigens can be presented to lymphocytes, inducing expansion of lymphocytes that recognize the tumor antigen. Because the response occurs in a 1-like cytokine environment, the lymphocyte response tends to be 1-like, including cytotoxic T lymphocytes. 16 To assess whether the CpG-rich adenovirus would use the same mechanisms, an immunecompetent mouse model was utilized. In this model, we observed that Ad5D24-CpG was able to control tumor growth more e ciently than the control viruses.
us, the e ect is probably related to the ability of the viruses to stimulate an immune response towards the tumor.
Our results are well in line with Tuve and colleagues, who observed that even unarmed replication de cient adenovirus, if used at high enough doses, can induce a speci c antitumor immune response. 9 ese data are not surprising given that adenovirus has the capability to stimulate several receptors of the innate immune system including TLR 2 and 9, 27, 28 NOD-like receptors, 43 and complement. 44 However, several clinical studies have indicated that adenovirus alone is not enough to cure advanced tumors. 5, [7] [8] 45 us, the approach of genetically modifying the adenovirus to improve its capacity for stimulation of receptors involved in tumor rejection (e.g., TLR9) could be an exciting opportunity for improving oncolytic adenovirus e cacy.
Interestingly, we found that Ad5D24-CpG showed increased e cacy compared with the combination of Ad5D24 and recombinant CpG oligonucleotides. We can speculate that this di erence is due to two mechanisms: (i) oncolytic adenoviruses have the ability to replicate in tumors resulting in ampli cation of the amount of DNA with CpG islands; (ii) the adenovirus genome is directly and e ciently delivered to the endosome in contrast to oligonucleotides which have to overcome several obstacles to reach the target receptor following intratumoral or intraperitonel administration.
We believe that most of the e ect shown by Ad5D24-CpG is due its capacity to trigger NK and T cell antitumor response; however, given the recent nding that TLR9 stimulation by CpG oligos can trigger a suppression of myeloid-derived suppressor cells, 18 we sought to investigate whether a similar e ect could be observed also in the context of adenovirus-mediated TLR9 stimulation. Interestingly, we observed that Ad5D24-CpG therapy signi cantly reduced the suppression mediated by MDSCs in B16-OVA model. Although these are preliminary ndings that would deserve a deeper experimentation and understanding of the all phenomenon, we do believe they are worth to be reported as overall contribution to Ad5D24-CpG activity and to eventually open new frontiers in the study of the mechanisms of action of oncolytic adenovirus.
In summary, our results indicate that Ad5D24-CpG shows an appealing e cacy and immunogenicity improvement compared with Ad5D24. e insertion of CpG islands into the genome of the adenovirus has conferred the ability to overstimulate TLR9 and triggers a more robust immune response. is approach addresses the weaknesses of both oncolytic adenovirus-mediated immunotherapy (low immunogenicity of an unmodi ed backbone) and CpG therapy (poor delivery to TLR9, systemic side e ects). Further, the small genome size and the intact multi-cloning sites of this novel oncolytic adenovirus represent an optimal backbone to insert transgenes by rationale design that can synergize with TLR9 stimulation and innate immune system activation to increase tumor clearance even further.
MATERIALS AND METHODS

Construction of adenoviruses.
Ad5D24 was generated and propagated with standard protocol as previously described.
5 Ad5D24-CpG was generated recombining a CpG-rich shuttle plasmid (pTHSN-CpG1) with a plasmid containing the 24 adenovirus backbone. pTHSN-CpG1 was constructed by inserting NdeI-digested CpG1 (derived by digestion from custom designed pU57-CpG1; GenScript, Piscataway, NJ) and SpeI-digested CpG2 sequences (derived by digestion from custom designed pU57-CpG1; GenScript) respectively into NdeI-and SpeIlinearized plasmid pTHSN previously generated. CpG insertion was conrmed by enzyme digestion and sequencing using the following primers: CpG-NdeI400 forward: 5-TTGTGTGGAATTGTGAGCGG-3; CpGNdeI400 reverse: 5-CTCCTGGCTGCAAACTTTCT-3; CpG-SpeI400 forward: 5-AACGACGGCCAGTGAATTGT-3; CpG-SpeI400 reverse: 5-GTAGGGCGTGGGAATTTCCT-3.
pTHSN-CpG1 was then recombined with pAd5D24 to obtain pAd5D24-CpG. e CpG-rich oncolytic adenovirus Ad5D24-CpG was then obtained with standard procedure. A er obtaining the virus, its structure and insertion of the CpG islands were analyzed with the following primers: E3 transg forward: 5-CAACCCAGACGGAGTGAGT-3; E3 transg reverse: 5-CCTGACTTCAAGGTTGTAGC-3; CpG-MscI forward: 5-CGATTGGCCATGAATTCCATATGTCGT-3; CpG-MscI reverse: 5-TTACTGGCCACTTCATATGATCAACGT-3.
Cell lines.
Human transformed embryonic kidney cell line 293 stably expressing human TLR9 (293XL-TLR9) was purchased from InvivoGen Europe (Toulouse, France). Human lung adenocarcinoma cell line A549, epithelian cervical carcinoma Hela, and 293 cell line were purchased from the American Type Culture Collection (Manassas, VA).
Ovarian carcinoma cells expressing re y luciferase, SKOV3-luc were provided by Dr Robert Negrin (Stanford Medical School, Stanford, CA).
PC3MM2 are highly metastatic prostate cancer cells that were gently obtained from Isaiah J Fidler, MD Anderson Cancer Center, Houston, TX. B16-OVA cell line was kindly provided by Professor Richard Vile at Mayo Clinic (Rochester, MN). All cell lines were cultured in the recommended conditions. NF B activation assay. To assay TLR9 stimulation via CpG island, 293XL-hTLR9 were plated at a density of 2 × 10 5 cells/well on 2 × 24 well/plates and cultured overnight. Monolayers in triplicates were transfected using SuperFect reagent (Qiagen, Valencia, CA) with 1 µg of reporter plasmid pNiFty-Luc (InvivoGen) which carries the luciferase reporter gene driven by an NFB-inducible ELAM-1 composite promoter able to respond to TLR9 stimulation. Green uorescent protein-expressing plasmid was used as control of transfection. A er 24 hours, cells were stimulated for 2 hours with Ad5D24-CpG or Ad5D24 and a cell lysate was obtained by adding a report lysis bu er in each well. A er a freeze/thaw cycle, luciferase activity in 20 µl of cell lysates was assayed, using 100 µl of a commercially available bu er system (Promega, Mannheim, Germany), according to the manufacturer's instructions.
Tumor cell-killing assay. Cell viability was assessed by MTS assay as described elsewhere. Brie y, cells were seeded at the concentration of 0.5 × 10 5 cells/well on 96-well plate and maintained under appropriate condition (RPMI 1640 or DMEM, completed with 10% FCS, 2 mmol L-glutamine, and 100 units/ml of penicillin (all from Sigma-Aldrich, St Louis, MO)). At the indicated time point, cell viability was assessed using CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega), i.e., the inner salt (MTS) assay and compared with their control.
Mice and animal experiments. All animal protocols were reviewed and approved by the Experimental Animal Committee of the University of Helsinki and the Provincial Government of Southern Finland. Mice were obtained from Taconic (Ejby, Denmark) at 4-5 weeks of age and quarantined at least for 2 weeks before the study. Health status of the mice was frequently monitored and as soon as sign of pain or distress was evident they were killed. e toxicity analysis was performed in C57BL/6 mice. Immunocompetent C57BL/6 mice (N = 8 per group) were intravenously injected with high dose (5 × 10 12 VP/kg and ~1 × 10 10 VP/mouse) of virus (Ad5D24 and Ad5D24-CpG) while PBS was used as negative control. Histopathological analysis of the livers was assessed as described previously. [46] [47] [48] e immunogenicity of the CpG-rich backbone was tested in immunocompetent C57BL/6 mice (N = 4 per group) intramuscularly injected with 1 × 10 8 VP of virus (Ad5D24, Ad5D24-CpG, and PBS as control), 21 days a er the immunization mice were euthanized, splenocytes were harvested, pulsed with Ad5-speci c peptides and IFN- ELISPOT was performed (Mabtech, Stockholm, Sweden).
Viral replication in clot and liver was assessed in immunocompetent C57BL/6 mice. ree groups of mice (N = 12 per group) were intravenously injected with Ad5D24, Ad5D24-CpG, and PBS at the dose of 1 × 10 12 VP/ kg, three mice per group were euthanized at 6 hours, 72 hours, 6 days, and 9 days and quantitative PCR was performed on liver and clots.
For the immune-de cient models, 10 6 A549 cells were injected subcutaneously into anks of nude mice (n = 5-7 mice/group). When tumors reached the size of ~5 × 5 mm, virus was injected intratumorally at 10 8 VP/tumor at indicated time points. For the immunocompetent model, 5 × 10 5 B16-OVA cells were injected subcutaneously on shaved anks of C57 black mice (n = 4 mice/group). Virus was injected intratumorally at 1 × 10 9 VP/tumor on days 0, 2, and 4, starting when tumors reached the size of ~5 × 5 mm.
CpG oligonucleotides (TLR9 stimulator, ODN 2395 5-tcgtcgttttcggcgc:gcgccg-3; InvivoGen) was resuspended in PBS at a concentration of 10 g/ml and premixed to the vector before intratumor injection. When injected alone ODN 2395 was simply resuspended in PBS. All the injections were performed with a total volume of 500 l. TLR9-blockers (ODN2088, 5-tcctggcggggaagt-3; InvivoGen) were intraperitoneally administered every second day. Oligos were administrated at the dose of 100 g for mouse per injection.
NK depletion was obtained by intraperitoneal administration of 50 l of anti-asialo GM1 (rabbit) antibody every 4 days (Wako Chemicals, Neuss, Germany) according to manufacturer's instruction. Each package of antibody comes with a titration for in vivo and in vitro use expressed in microliter.
Quantitative PCR for detection of adenovirus was performed as described by us elsewhere. 49 Tumor growth was followed and organs/ tumors were collected at the end of the experiments. Spleens were minced and splenocytes were cultured in 10% Dulbecco's modi ed Eagle's medium supplemented with 1% L-glutamine and penicillin/streptomycin for ow cytometry and cytokine analysis.
Flow cytometry analysis. Single cell suspensions were stained with uorochrome-conjugated monoclonal antibodies and analyzed using a FACSARIA ow cytometer (BD Biosciences, Palo Alto, CA) and FlowJo so ware (TreeStar, Ashland, OR). For MDSCs, the following antibodies were used: mouse CD11b (PE-Cy7 labeled, RAT IgG2b,k isotype), mouse Gr-1 (Ly6G and Ly6C) (FITC labeled, RAT IgG2b,k isotype), and mouse Ly-6G (PE öabeled, RAT IgG2a,k isotype) all antibodies were purchased from (BD Biosciences). MDSCs-like population was de ned as Gr-1 + CD11b + while reduction in the proportion of Ly6G was used as a marker of suppressive activity of the cell. 11, 18 For anti-OVA-speci c pentamer analysis, we used mouse CD8 (FITC labeled, IgG2a isotype), mouse CD19 (PE-Cy7 labeled, RAT IgG2a isotype), and mouse SIINFEKL MHC-I pentamer (PE-labeled). Antibodies were purchased from PROIMMUNE (Oxford, UK). NK cells and lysis was performed using the anti mouse NK1.1 (FITC labeled, Mouse IgG2a,k isotype) from eBioscience (San Diego, CA).
Tumor cell suspensions were obtained by digesting dissected tumor tissues with collagenase D (1 mg/ml) and DNase I (0.05 mg/ml, both from Sigma-Aldrich, Steinheim, Germany) for 40 minutes at 37 ºC and subsequent passage through a 70 m pore cell mesh. Analysis was performed using a FACSCanto II ow cytometer (BD Biosciences) and FlowJo so ware (TreeStar).
Cytokine analysis. Mouse IFN-, IL-2, TNF-, RANTES (regulated upon activation, normal T-cell expressed, and secreted) were assayed using the BD cytokine multiplex bead array system (BD Biosciences), and analyzed using BD FacsArray (BD Biosciences) according to the manufacturer's instructions.
Statistical analysis. Statistical signi cance was determined by unpaired Student's t-test using GraphPad Prism 5 (GraphPad So ware, San Diego, CA). Comparison of multiple groups was performed using one-way analysis of variance with pair-wise Bonferroni post-tests. Tumor sizes were analyzed using the Mann-Whitney U-test. All data are expressed as mean  SEM. A two-tailed P value of <0.05 was considered signi cant. 
SUPPLEMENTARY MATERIAL
